NATCO launches additional strengths for generic version of Revlimid in USA
News

NATCO launches additional strengths for generic version of Revlimid in USA

Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

  • By IPP Bureau | March 10, 2023

NATCO Pharma Limited announces the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries. 

With this launch the companies made available all the strengths of lenalidomide in the US market. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International